KidneyCAN is dedicated to accelerating kidney cancer research

Our advocacy for the DOD Kidney Cancer Research Program resulted in appropriations of  $40 million in fiscal year 2020  for kidney cancer research. In 2016, this number was $0.

Our Kidney Cancer Research Summit brings translational researchers in kidney cancer together in an annual collaborative meeting.  Additionally, KidneyCAN’s  “Rock the Cure” events have raised over $1,000,000 toward private research support.

KCRS20

KidneyCAN is proud to announce the second annual Kidney Cancer Research Summit, a meeting focused on basic and translational science, as well as cutting edge translational research. This work is fueled by the funding from the Department of Defense CDMRP – KCRP.  

The Kidney Cancer Research Summit (KCRS20) is scheduled for October 22nd-23rd in Philadelphia, Pennsylvania. We will meet at the Convene CityView Conference Center. Join us as we continue to fight for a cure! 

Registration for this event is now open for Academic/Research attendees and Industry Representatives. Questions? Contact us at [email protected]

REGISTER FOR KCRS20
We're counting down!
0
0
0
Weeks
0
0
0
0
Days
0
0
Hrs
0
0
Min
0
0
Sec

KCRS19

The Kidney Cancer Research Summit (KCRS19) took place on September 12-13, 2019. Led by Dr. Toni Choueiri (Dana Farber Cancer Institute) and Dr. Hans Hammers (University of Texas Southwest Medical Center), this event brought together some of the most promising ideas for treatment. 

KidneyCAN gathered 150 of the key thought leaders in the kidney cancer field. Researchers, scientists, and clinicians, along with government and industry partners, had an opportunity to gather in one location and share their latest findings in a collaborative and discussion-centric environment.

KCRS19 Presentations

If you missed KCRS19, you can review the presentation content here. 

“This is what started as a grassroots meeting for the entire RCC community, focusing on science, ultimate collaboration, and inclusiveness. All in the hope of helping our patients live better,  live longer, and dream of the cure. Why not? Isn’t that what we all want if we get this disease?

I feel this is the beginning of something very, very special.”

Toni Choueiri, MD, Dana-Farber Cancer Institute

“It’s one of the most exciting things I’ve ever participated in. We’re bringing together clinicians, physician scientists, and bench scientists to talk about kidney cancer research. The goal is to invigorate the science and spur breakthroughs.”

Hans Hammers, MD, PhD, UT Southwestern Medical Center

Single Cell Sequencing Strategies in Kidney Cancer

Moderated by Payal Kapur & Sabina Signoretti

Introduction to Single Cell Sequencing in Solid Cancers (Ari Hakimi)

Single Cell Architecture of Mitochondrial DNA Mutations in RCC (Eduard Reznik)

Using Single-Cell Transcriptomics to Understand Tumor and Immune Heterogeneity Driving Resistance (David Braun)

Scientific Mentoring Session Powered by the American Urological Association

Introduction to AUA (Carolyn Best)

Introduction to Scientific Mentoring Session (Brian Rini)

Poster Sessions from AUA by Ken Batai, Phillip Abbosh, Vivek Narayan, and Brandon Manley (R. Uzzo, B. Shuch, A. Kutikov, E. Singer, G. Bratslavsky)

Novel Checkpoint Inhibitors and Cellular Immunotherapy

Moderated by Hans Hammers & Charles Drake

Is VISTA:VSIG3 an Actionable Immune Checkpoint Target (Kathleen Mahoney)

Identification of a New Immune Checkpoint Pathway in RCC (Rupal Bhatt)

Development and Potentials for ImmunoPET Imaging (David Leung)

HERV-E TCR Transduced Autologous T Cells (Rosa Nadal)

Overview of Cellular Therapies: CAR-T (Regina Young, introduction by Naomi Haas)

Targeting B7-H3 in Renal Cell Carcinoma via CAR-T Cells (Hongwei Du)

Design of Dual Targeted CAR-T Cells to Improve RCC Treatment Safety (Wayne Marasco)

Translational Variants in Rare Kidney Cancers

Moderated by Marston Linehan & Kim Rathmell

Setting the Stage to Research and Collaborations in Rare Kidney Cancer Variants (James Hsieh)

Novel Function of the Tumor Suppressor FLCN in Rare Kidney Cancer (Mehdi Mollapour)

Chromophobe RCC: New Insights (Elizabeth Henske)

Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma (Pavlos Msaouel)

Therapeutic Targeting TFE3 in Translocation Renal Cell Carcinoma (Roberto Pili & Nur Damayanti)

Papillary RCC (Brian Shuch, with Nizar Tannir)

“Kidney cancer is the ideal sandbox for these new approaches, and without a doubt the same approach can, should and will be suitable for other cancers.”

Dr. Hans Hammers

JOIN OUR COMMUNITY
Stay in Touch: Join The Kidney Cancer Coalition Email List!

Please enter your information below: